From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Arecor Therapeutics – less than a month after ‘going concern on base case with mitigations’, already “working capital requirements have accelerated”. Uh oh!…

By Steve Moore | Monday 10 June 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Arecor Therapeutics (AREC) has issued a “Trading and Funding Update” announcement including that it “currently expects that revenue for 2024 remains in line with consensus market expectations” and that it “is examining potential cost mitigation in the near term”. So what of a current approaching 20% lower share price response to 127.5p?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

HAT

H&T Group – now again a Buy

Time left: 11:34:56